1. Home
  2. TCBK vs DMRA Comparison

TCBK vs DMRA Comparison

Compare TCBK & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriCo Bancshares

TCBK

TriCo Bancshares

HOLD

Current Price

$51.26

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$22.00

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TCBK
DMRA
Founded
1975
2011
Country
United States
United States
Employees
N/A
7
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
TCBK
DMRA
Price
$51.26
$22.00
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$54.60
$43.00
AVG Volume (30 Days)
106.9K
316.7K
Earning Date
04-23-2026
05-11-2026
Dividend Yield
2.87%
N/A
EPS Growth
6.94
N/A
EPS
1.04
N/A
Revenue
$53,445,000.00
N/A
Revenue This Year
$12.03
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$49.27
N/A
Revenue Growth
4.12
N/A
52 Week Low
$39.84
$16.50
52 Week High
$53.18
$28.76

Technical Indicators

Market Signals
Indicator
TCBK
DMRA
Relative Strength Index (RSI) 53.42 41.75
Support Level $48.57 $18.59
Resistance Level $53.18 $27.70
Average True Range (ATR) 1.22 1.99
MACD 0.01 -0.06
Stochastic Oscillator 58.12 36.16

Price Performance

Historical Comparison
TCBK
DMRA

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: